- Companies
- CHARM Therapeutics
CHARM Therapeutics Funding, Investors & Competitors
CHARM Therapeutics has raised $163M across 4 funding rounds, most recently a $80M Series B in September 2025.
Last CHARM Therapeutics funding round
$80M
Series B · Sep 2025
Cumulative funding CHARM Therapeutics raised
$163M
across 4 funding rounds
Key investors in CHARM Therapeutics
Khosla Ventures
OrbiMed
F-Prime
General Catalyst
New Enterprise Associates
NVIDIA
SR One
NVentures
About CHARM Therapeutics
CHARM Therapeutics is an Oxford-based biotech firm developing small-molecule drugs targeting menin-KMT2A interactions for acute myeloid leukemia. Its DragonFold AI platform designs inhibitors active against resistance mutations, advancing a lead candidate from preclinical to Phase 1 trials. The company collaborates with UK research institutes on protein-ligand modeling.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
CHARM Therapeutics Funding History
CHARM Therapeutics has raised a total of $163M across 4 funding rounds.
CHARM Therapeutics' first fundraising round was a $13M Series A in October 2021. The most recent completed round was a $80M Series B in September 2025.
CHARM Therapeutics funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Sep 2025 | Series B | New Enterprise Associates (lead); SR One (lead); NVIDIA; F-Prime; Khosla Ventures; OrbiMed | $80M | CHARM Therapeutics, a UK-based biotechnology company with operations in Cambridge and London, closed an oversubscribed $80 million Series B funding round on September 2, 2025, co-led by New Enterprise Associates (NEA) and SR One, with participation from existing investors OrbiMed, F-Prime, Khosla Ventures, and NVIDIA. The company, co-founded by Nobel laureate David Baker, leverages its proprietary DragonFold AI-driven drug discovery platform to develop next-generation precision oncology treatments, specifically a menin inhibitor designed to overcome resistance mutations in first-generation therapies for acute myeloid leukemia (AML). This candidate aims for superior efficacy, durability, and safety, including reduced risk of cardiac arrhythmia and drug-drug interactions at low doses, with clinical development targeted to start in Q1 2026. The funding will advance the lead menin inhibitor into first-in-human trials early 2026, following strong preclinical data. CHARM has now raised over $150 million cumulatively from leading international investors. The round underscores investor confidence in CHARM's breakthrough approach amid limitations of prior menin inhibitors like Syndax's FDA-approved revumenib (Revuforj). In parallel, the company strengthened its board with oncology experts Briggs Morrison, M.D. (former Syndax CEO), Kim Blackwell, M.D., and investor representatives Matthew McAviney (NEA) and Mahesh Kudari (SR One). CHARM positions itself in the competitive AML landscape, targeting treatment-resistant cancers with limited options. Cooley advised on the financing, and the company recently saw a leadership transition with co-founder Laksh Aithani departing as CEO but remaining on the board, while Gary Glick serves as executive chairman. A new chief medical officer is expected to be announced soon. |
| Apr 2023 | Undisclosed stage | NVentures (lead) | $20M | - |
| Jun 2022 | Series A | F-Prime (lead); OrbiMed (lead); General Catalyst; Khosla Ventures; Saya Bio; Braavos Investment Advisers; Axial VC | $50M | CHARM Therapeutics, a London-based biotechnology company co-founded by David Baker, Ph.D., and Laksh Aithani, uses 3D deep-learning and AI, including its proprietary DragonFold protein-ligand co-folding platform, to discover and develop small molecule therapeutics against hard-to-drug targets in cancer and other areas. The company announced a $50 million Series A financing on June 9, 2022, co-led by F-Prime Capital and OrbiMed, with participation from General Catalyst, Khosla Ventures, Braavos, Axial, and Grep VC. Gary D. Glick, Ph.D., serial biotech entrepreneur and founder of IFM Therapeutics, Scorpion Therapeutics, and Odyssey Therapeutics, joined as Executive Chair. The Series A funding supported building an interdisciplinary team combining AI, drug discovery, and structural biology expertise to redefine drug discovery processes. Investors highlighted CHARM's world-class team and the breakthrough in AI-driven protein structure prediction for life sciences. Subsequently, CHARM raised additional capital, including a $20.05 million Series A-II on May 15, 2023, and an oversubscribed $80 million Series B on September 2, 2025, co-led by New Enterprise Associates (NEA) and SR One, with participation from OrbiMed, F-Prime, Khosla Ventures, and NVIDIA, bringing total funding over $150 million. The Series B advances a next-generation menin inhibitor for AML that overcomes resistance mutations, with clinical development planned for early 2026. |
| Oct 2021 | Series A | - | $13M | CHARM Therapeutics raised $13 million in a Seed VC round on October 22, 2021. The company develops a deep learning platform to deliver transformational medicines through 3D deep learning and computational protein design. Founded in 2021 and based in London, United Kingdom, it focuses on precision oncology treatments using an AI-driven drug discovery platform. This seed funding preceded later rounds, including a $37 million Series A announced in June 2022, which valued the firm between $100 million and $150 million post-money and brought total funding to $50 million. Investors in early rounds included OrbiMed, F-Prime Capital, Khosla Ventures, and General Catalyst. The company has since advanced programs like a next-generation menin inhibitor for acute myeloid leukemia (AML). |
Who has invested in CHARM Therapeutics?
11 investors have backed CHARM Therapeutics across its funding rounds, including Khosla Ventures, OrbiMed, F-Prime, General Catalyst, New Enterprise Associates and NVIDIA.
Lead investors include New Enterprise Associates, SR One, NVentures, F-Prime and OrbiMed.
CHARM Therapeutics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Jun 2022 | ||
| 2 | Participant | Jun 2022 | ||
| 2 | Lead | Jun 2022 | ||
| 1 | Participant | Sep 2025 | ||
| 1 | Participant | Jun 2022 | ||
| 1 | Lead | Apr 2023 | ||
| 1 | Lead | Sep 2025 | ||
| 1 | Lead | Sep 2025 | ||
| 1 | Participant | Jun 2022 | ||
This data is available for Pro users. Sign up to see all 11 CHARM Therapeutics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialCHARM Therapeutics Competitors
CHARM Therapeutics competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Private | $47B | - | $965B | 20.5x | ||
| Private | $25B | - | $852B | 34.1x | ||
| Publicly listed | $42B | $13B | $248B | 5.4x | ||
| Publicly listed | $4.7B | ($1.3B) | $119B | 21.0x |
CHARM Therapeutics Public Comps
CHARM Therapeutics is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
This data is available for Pro users. Sign up to see all CHARM Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about CHARM Therapeutics
| When was CHARM Therapeutics founded? | CHARM Therapeutics was founded in 2021. |
| Where is CHARM Therapeutics headquartered? | CHARM Therapeutics is headquartered in London, United Kingdom. |
| Is CHARM Therapeutics publicly listed? | No, CHARM Therapeutics is a private, VC-backed company. |
| How much funding has CHARM Therapeutics raised? | CHARM Therapeutics has raised $163M across 4 funding rounds. |
| What was CHARM Therapeutics' last funding round? | CHARM Therapeutics' last funding round was a $80M Series B in September 2025, led by New Enterprise Associates and SR One. |
| Who are CHARM Therapeutics' investors? | CHARM Therapeutics' investors include F-Prime, Khosla Ventures, OrbiMed, NVIDIA, General Catalyst, NVentures, New Enterprise Associates, SR One, Saya Bio, Braavos Investment Advisers and 1 other. |
| Which companies are comparable to CHARM Therapeutics? | Companies comparable to CHARM Therapeutics include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake. |
See companies similar to CHARM Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




